All In Biotech

Drug Trial Radar · NCT03357614

Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults

Prospective, Phase 3, Randomized, Multi-center, Double-blind, Double-dummy Study of Efficacy, Tolerability & Safety of Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Treatment of cUTI in Adults

Last checked: Nov 19, 2026Latest source record: Dec 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,395 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,395

Actual

Start

Sep 18, 2018

Primary completion

Dec 14, 2019

Study completion Dec 14, 2019

Sponsor

Sponsor type
Industry
First posted
Nov 30, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, phase 3, randomized, multicenter, double-blind, double-dummy study to compare the efficacy and safety of sulopenem followed by sulopenem-etzadroxil/probenecid versus ertapenem followed by ciprofloxacin for the treatment of complicated urinary tract infections (cUTI) in adults.

Conditions

  • Complicated Urinary Tract Infections

Interventions

  • SulopenemDrug

    Antibiotic therapy for complicated UTI

  • Sulopenem-Etzadroxil/ProbenecidDrug

    Antibiotic therapy for complicated UTI

  • ErtapenemDrug

    Antibiotic therapy for complicated UTI

  • CiprofloxacinDrug

    Antibiotic therapy for complicated UTI

  • Amoxicillin-clavulanateDrug

    Antibiotic therapy for complicated UTI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Overall SuccessTime frame: Day 21 +/- 1 day

Locations

32 sites in 5 countries. Site status is shown where the registry gives one.

  • Medical Facility

    Bellflower, California

  • Medical Facility

    Chula Vista, California

  • Medical Facility

    La Mesa, California

  • Medical Facility

    La Palma, California

  • Medical Facility

    Torrance, California

  • Medical Facility

    Miami Lakes, Florida

  • Medical Facility

    Columbus, Georgia

  • Medical Facility

    Idaho Falls, Idaho

  • Medical Facility

    Boston, Massachusetts

  • Medical Facility

    Royal Oak, Michigan

  • Medical Facility

    Butte, Montana

  • Medical Facility

    Columbus, Ohio

  • Medical Facility

    Columbus, Ohio

  • Medical Facility

    Dallas, Texas

  • Medical Facility

    Houston, Texas

  • Medical Facility

    Kohtla-Järve, Estonia

  • Medical Facility

    Tallinn, Estonia

  • Medical Facility

    Võru, Estonia

  • Medical Facility

    Tbilisi, Georgia

  • Medical Facility

    Tbilisi, Georgia

  • Medical Facility

    Tbilisi, Georgia

  • Medical Facility

    Baja, Hungary

  • Medical Facility

    Budapest, Hungary

  • Medical Facility

    Nagykanizsa, Hungary

  • Medical Facility

    Nyíregyháza, Hungary

  • Medical Facility

    Szentes, Hungary

  • Medical Facility

    Tatabánya, Hungary

  • Medical Facility

    Daugavpils, Latvia

  • Medical Facility

    Liepāja, Latvia

  • Medical Facility

    Riga, Latvia

  • Medical Facility

    Riga, Latvia

  • Medical Facility

    Valmiera, Latvia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.